GlassScriptPhysician profile
Catherine A Frank
NPI 1245213800
$2,568.45
in general payments reported to CMS, 2019-2025
35 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $164 · 2021: $444 · 2022: $527 · 2023: $613 · 2024: $539 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $498.94 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $345.86 | 2019-2025 | |
| Abbott Laboratories | $234.39 | 2022-2024 | Freestyle Libre 3, Proclaim, Jot Dx |
| Astellas Pharma US INC | $233.18 | 2021-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.39 | 2020-2024 | Jardiance |
| Pfizer INC. | $133.12 | 2022-2025 | |
| Glaxosmithkline, LLC. | $129.42 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $93.00 | 2022-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $78.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $73.18 | 2020-2022 | |
| Lilly USA, LLC | $65.56 | 2023-2025 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.15 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $45.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.86 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $34.89 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $34.00 | 2021 | |
| Eisai INC. | $27.40 | 2020-2021 | |
| Vistapharm, INC. | $26.19 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.09 | 2023 | Keveyis |
| Sanofi-Aventis U.S. LLC | $22.69 | 2023 | |
| Phathom Pharmaceuticals, INC. | $22.64 | 2024 | Voquezna |
| Upsher-Smith Laboratories LLC | $20.67 | 2019 | |
| Esperion Therapeutics, INC. | $20.12 | 2021 | |
| Medtronic, INC. | $18.34 | 2021 | |
| Hologic Sales and Service, LLC | $18.30 | 2023 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $17.79 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.13 | 2020 | |
| Sanofi Pasteur INC. | $15.09 | 2020 | |
| Exact Sciences Corporation | $15.03 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.34 | 2023 | |
| Medtronic USA, INC. | $14.02 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.18 | 2021 | |
| Medtronic Vascular, INC. | $12.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.